We are live on ! Find out more
EDIT icon

Editas Medicine

99 hedge funds and large institutions have $614M invested in Editas Medicine in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

88% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $381M → $614M (+$233M)

18% more funds holding

Funds holding: 8499 (+15)

3.54% more ownership

Funds ownership: 64.09%67.63% (+3.5%)

31% less call options, than puts

Call options by funds: $5.38M | Put options by funds: $7.75M

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
35
Increased
32
Reduced
17
Closed
15
Calls
$5.38M
Puts
$7.75M
Net Calls
-$2.37M
Net Calls Change
-$2.61M
Name Holding Trade Value Shares
Change
Change in
Stake
TCIM
51
TIAA CREF Investment Management
New York
$410K -$48.1K -2,319 -11%
Citadel Advisors
52
Citadel Advisors
Florida
$363K +$337K +16,267 New
California State Teachers Retirement System (CalSTRS)
53
California State Teachers Retirement System (CalSTRS)
California
$344K +$26.9K +1,300 +9%
TA
54
Teachers Advisors
New York
$329K +$78.3K +3,779 +35%
EMG
55
Ellington Management Group
Connecticut
$304K +$282K +13,600 New
FRM
56
Fox Run Management
Connecticut
$272K +$253K +12,200 New
DTL
57
Dynamic Technology Lab
Singapore
$269K +$250K +12,059 New
MF
58
Magnetar Financial
Illinois
$267K +$248K +11,982 New
SSA
59
Schonfeld Strategic Advisors
New York
$242K +$225K +10,858 New
Simplex Trading
60
Simplex Trading
Illinois
$241K +$83.6K +4,036 +59%
PCC
61
Park Circle Company
Maryland
$223K
BAM
62
Barrett Asset Management
New York
$223K +$207K +10,000 New
Squarepoint
63
Squarepoint
New York
$216K -$214K -10,328 -52%
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$201K +$51.7K +2,496 +38%
SCM
65
Sterling Capital Management
North Carolina
$201K +$187K +9,000 New
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$145K +$21 +1 +0%
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$145K +$81.7K +3,944 +153%
Bank of America
68
Bank of America
North Carolina
$133K +$51.6K +2,489 +72%
CG
69
Cutler Group
California
$114K +$106K +5,130 New
AIG
70
American International Group
New York
$94K +$5.82K +281 +7%
NFA
71
Nationwide Fund Advisors
Ohio
$92K -$12.7K -613 -13%
QT
72
Quantbot Technologies
New York
$92K +$85.9K +4,146 New
HHMI
73
Howard Hughes Medical Institute
Maryland
$62K -$104 -5 -0.2%
Legal & General Group
74
Legal & General Group
United Kingdom
$47K -$3.36K -162 -7%
FPF
75
FNY Partners Fund
New York
$44K +$41.4K +2,000 New

EDIT Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2017, worth a combined $614M — up 61% from $381M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new EDIT positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 17 trimmed.

The largest buyer was Capital World Investors, adding an estimated $30.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.2M sold.

  • 99 institutional investors held Editas Medicine (EDIT) as of Q1 2017, up from 84 in Q4 2016.
  • Funds reported $614M of Editas Medicine stock for Q1 2017, up 61% quarter-over-quarter.
  • 35 funds opened new Editas Medicine positions in Q1 2017 and 15 closed out, a net change of +20 holders.
  • The largest Editas Medicine buyer in Q1 2017 was Capital World Investors, an estimated $30.6M added.
  • The largest Editas Medicine seller in Q1 2017 was EcoR1 Capital, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2017.